Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study - PubMed
10 hours ago
- #alopecia areata
- #JAK inhibitors
- #pharmacovigilance
- JAK inhibitors for alopecia areata show varied post-marketing safety signals across agents.
- Tofacitinib associated with neuropsychiatric and autoimmune events; baricitinib with thrombocytosis, DVT, and breast cancer.
- Ruxolitinib linked to pyrexia and elevated cholesterol; ritlecitinib with gastrointestinal issues and CPK elevation.
- Time-to-onset differs: earlier for tofacitinib/ruxolitinib, clustered first month for ritlecitinib, delayed for baricitinib.
- Serious outcomes often infection-related, but clinical outcomes vary by agent, suggesting need for agent-specific monitoring.